News Related to Checkpoint Inhibitor Therapy

Related coverage linked through entity extraction aliases.

TuHURA gains FDA orphan drug designation for IFx-2.0 in cutaneous melanoma

May 17, 2026

TuHURA Biosciences said the FDA granted orphan drug designation to IFx-2.0 for stage IIB to stage IV cutaneous melanoma based on Phase 1 data. The company said its Phase 3 IFx-2.0 study in first-line Merkel cell carcinoma continues to enroll.

ImmunityBio Reports 700% Revenue Growth, Expands Anktiva to 33 Countries and Lung Cancer

Feb 24, 2026

ImmunityBio announced $113 million in net product revenue for Anktiva in 2025, a 700% year-over-year increase, while expanding regulatory authorization to 33 countries and securing first approval for lung cancer treatment in Saudi Arabia.